Compare ANNX & BZH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | BZH |
|---|---|---|
| Founded | 2011 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.4M | 672.0M |
| IPO Year | 2020 | 1995 |
| Metric | ANNX | BZH |
|---|---|---|
| Price | $5.47 | $19.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $16.50 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.2M | 349.2K |
| Earning Date | 03-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.94 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,087,739,000.00 |
| Revenue This Year | N/A | $4.36 |
| Revenue Next Year | N/A | $10.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.29 | $17.37 |
| 52 Week High | $7.18 | $28.33 |
| Indicator | ANNX | BZH |
|---|---|---|
| Relative Strength Index (RSI) | 49.49 | 22.99 |
| Support Level | $4.77 | N/A |
| Resistance Level | $5.61 | $24.10 |
| Average True Range (ATR) | 0.35 | 0.72 |
| MACD | 0.01 | -0.41 |
| Stochastic Oscillator | 33.89 | 6.84 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.